Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548524 | 0.81 | KDM4E (0.37) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL9971234 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL6597830 | 0.79 | SORD (0.47) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL1514912 | 0.79 | CYP1A2 (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL2263641 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL9934866 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL874900 | 0.79 | KMT2A (0.44) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL29756554 | 0.79 | KMT2A (0.44) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL30838793 | 0.79 | CYP1A2 (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL27664513 | 0.79 | MAPT (0.44) | KDM4EGPR3EGFRCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102918044-A | Fused quinazoline derivatives and uses thereof | SHENZHEN SALUBRIS PHARM CO LTD | 2013-02-06 | — | — | CN | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| CN-101421257-A | Agents that disrupt cellular replication and their use in inhibiting pathological conditions | EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) | 2009-04-29 | — | — | CN | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| CN-102918044-A | Fused quinazoline derivatives and uses thereof | SHENZHEN SALUBRIS PHARM CO LTD | 2013-02-06 | — | — | CN | disclosed |
| EP-2033952-B1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | SHIONOGI & CO (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2321319-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100204237-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase | MIKAMIYAMA HIDENORI | 2010-08-12 | — | — | US | disclosed |
| US-7759372-B2 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7745453-B2 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-1375486-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6576765-B2 | Process for preparing amic acid esters | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| US-20030032667-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-02-13 | — | — | US | disclosed |
| CN-1366523-A | Process for preparing amic acid esters | IHARA CHEMICAL IND CO (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-1182199-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-5409929-A | Treating psychosis, dyskinesia | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-25 | — | — | US | disclosed |
| US-5216018-A | Antidyskinetic agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204237-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase | HAT1, SULT1A1, CDK20 | KDM4E 930/4885GPR3 2016/4885EGFR 1686/4885 |
| US-20030032667-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | MCCC2, EMC1, GANC | KDM4E 2048/4885GPR3 2768/4885EGFR 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.